James E. Flynn

Insider Reports History

Reporting-owner location: New York, NY
Latest reporting-owner signature: /s/ Jonathan Isler, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for James E. Flynn

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

AdaptHealth Corp.

Security class: Class A Common Stock
Shares / value: 11,528,863
Estimated value: $123,358,834
Report date: 12 Mar 2024
Price: $10.70
Ownership: Through Deerfield Partners, L.P.

Form 4 holding 10%+ Owner

ARS Pharmaceuticals, Inc.

Security class: Class A Common Stock
Shares / value: 4,887,254
Estimated value: $90,218,708
Report date: 27 Jun 2025
Price: $18.46
Ownership: Through Deerfield Private Design Fund III, L.P.

Form 4 holding 10%+ Owner

ARS Pharmaceuticals, Inc.

Security class: Class A Common Stock
Shares / value: 4,887,254
Estimated value: $90,218,708
Report date: 27 Jun 2025
Price: $18.46
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class A Common Stock
Shares / value: 650,000
Estimated value: $66,592,500
Report date: 16 Jun 2026
Price: $102.45
Ownership: Deerfield Partners, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

CareMax, Inc.

Security class: Class A Common Stock
Shares / value: 15,811,090
Estimated value: $54,706,371
Report date: 17 Nov 2023
Price: $3.46
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 10,622,957
Estimated value: $53,114,785
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 10,622,928
Estimated value: $53,114,640
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Private Design Fund III, L.P.

Form 4 holding * Possible Member of 10% Group, 10%+ Owner

Mirum Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 1,704,244
Estimated value: $47,778,651
Report date: 06 Jun 2022
Price: $28.04
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding * Possible Member of 10% Group, 10%+ Owner

Mirum Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 1,540,190
Estimated value: $43,179,381
Report date: 06 Jun 2022
Price: $28.04
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 8,153,107
Estimated value: $40,765,535
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 6,207,982
Estimated value: $31,039,910
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Partners, L.P.

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

AdaptHealth Corp.

Security class: Class A Common Stock
Shares / value: 1,709,077
Estimated value: $18,287,124
Report date: 08 Mar 2024
Price: $10.70
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Bicara Therapeutics Inc.

Security class: Common Stock
Shares / value: 897,587
Estimated value: $11,887,104
Report date: 17 Sep 2024
Price: $13.24
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Bicara Therapeutics Inc.

Security class: Common Stock
Shares / value: 897,587
Estimated value: $11,887,104
Report date: 17 Sep 2024
Price: $13.24
Ownership: Through Deerfield Private Design Fund V, L.P.

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

Singular Genomics Systems, Inc.

Security class: Common Stock
Shares / value: 7,484,871
Estimated value: $3,169,094
Report date: 01 Jun 2021
Price: $0.4234
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding Director, Director by deputization

Acutus Medical, Inc.

Security class: Common Stock
Shares / value: 1,622,143
Estimated value: $2,530,543
Report date: 27 Jan 2025
Price: $1.56
Ownership: Through Deerfield Private Design Fund III, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Fractyl Health, Inc.

Security class: Common Stock
Shares / value: 834,254
Estimated value: $2,419,003
Report date: 06 Feb 2024
Price: $2.90
Ownership: Through Deerfield Private Design Fund III, L.P.

Form 4 holding Possible Member of 10% Group, 10%+ Owner

PepGen Inc.

Security class: Common Stock
Shares / value: 476,813
Estimated value: $1,985,926
Report date: 10 May 2022
Price: $4.16
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Possible Member of 10% Group, 10%+ Owner

PepGen Inc.

Security class: Common Stock
Shares / value: 476,813
Estimated value: $1,985,926
Report date: 10 May 2022
Price: $4.16
Ownership: Through Deerfield Private Design Fund V, L.P.

Form 4 holding Director, Director by deputization

Acutus Medical, Inc.

Security class: Common Stock
Shares / value: 1,026,243
Estimated value: $1,600,939
Report date: 27 Jan 2025
Price: $1.56
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Director, *Director by Deputization

BiomX Inc.

Security class: Common Stock
Shares / value: 1,247,054
Estimated value: $1,160,508
Report date: 27 Feb 2025
Price: $0.9306
Ownership: Through Deerfield Healthcare Innovations Fund II, L.P.

Form 4 holding Director, *Director by Deputization

BiomX Inc.

Security class: Common Stock
Shares / value: 1,247,054
Estimated value: $1,160,508
Report date: 27 Feb 2025
Price: $0.9306
Ownership: Through Deerfield Private Design Fund V, L.P.

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Xilio Therapeutics, Inc.

Security class: Common Stock
Shares / value: 1,143,972
Estimated value: $949,497
Report date: 26 Oct 2021
Price: $0.8300
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Xilio Therapeutics, Inc.

Security class: Common Stock
Shares / value: 1,143,972
Estimated value: $949,497
Report date: 26 Oct 2021
Price: $0.8300
Ownership: Through Deerfield Private Design Fund V, L.P.

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

Singular Genomics Systems, Inc.

Security class: Common Stock
Shares / value: 1,627,148
Estimated value: $688,934
Report date: 01 Jun 2021
Price: $0.4234
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class A Common Stock
Shares / value: 3,444
Estimated value: $352,837
Report date: 16 Jun 2026
Price: $102.45
Ownership: Through Deerfield Management Company, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Class A Common Stock
Shares / value: 1,605,477
Estimated value: $218,345
Report date: 12 Nov 2021
Price: $0.1360
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Class A Common Stock
Shares / value: 1,605,477
Estimated value: $218,345
Report date: 12 Nov 2021
Price: $0.1360
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

AdaptHealth Corp.

Security class: Class A Common Stock
Shares / value: 20,000
Estimated value: $214,000
Report date: 08 Mar 2024
Price: $10.70
Ownership: Through Deerfield Management Company, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

CareMax, Inc.

Security class: Class A Common Stock
Shares / value: 12,123
Estimated value: $41,946
Report date: 17 Nov 2023
Price: $3.46
Ownership: Through Deerfield Management Company, L.P.

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

Singular Genomics Systems, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 30,000
Estimated value: $33,000
Report date: 01 Jun 2021
Price: $1.10
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Common Stock
Underlying amount: 30,000

Form 4 holding Director, Director by deputization

Acutus Medical, Inc.

Security class: Common Stock
Shares / value: 20,822
Estimated value: $32,482
Report date: 27 Jan 2025
Price: $1.56
Ownership: Through Deerfield Management Company, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Class A Common Stock
Shares / value: 85,113
Estimated value: $11,575
Report date: 12 Nov 2021
Price: $0.1360
Ownership: Through Deerfield Management Company, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Class A Common Stock
Shares / value: 40
Estimated value: $5
Report date: 12 Nov 2021
Price: $0.1360
Ownership: Through DFP Sponsor, LLC

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class A Common Stock
Shares / value: 0
Estimated value: $0
Report date: 15 Jul 2026
Price: $123.50
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class A Common Stock
Shares / value: 0
Estimated value: $0
Report date: 15 Jul 2026
Price: $123.50
Ownership: Through Deerfield Mangement Company, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class A Common Stock
Shares / value: 0
Estimated value: $0
Report date: 15 Jul 2026
Price: $123.50
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class A Common Stock
Shares / value: 0
Estimated value: $0
Report date: 15 Jul 2026
Price: $123.50
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Private Placement Warrants
Shares / value: 3,177,543
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through DFP Sponsor, LLC
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Frazier Lifesciences Acquisition Corp

Security class: Class A Ordinary Shares
Shares / value: 2,480,199
Estimated value
Report date: 08 Nov 2022
Price
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Director, Director by deputization

Acutus Medical, Inc.

Security class: Series A Common Stock Equivalent Convertible Preferred Stock
Shares / value: 1,816,446
Estimated value
Report date: 27 Jan 2025
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Class A Common Stock
Underlying amount: 1,816,446

Form 4 holding Director, *Director by Deputization

BiomX Inc.

Security class: Warrants
Shares / value: 1,611,864
Estimated value
Report date: 21 Apr 2025
Price
Ownership: Through Deerfield Healthcare Innovations Fund II, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, *Director by Deputization

BiomX Inc.

Security class: Warrants
Shares / value: 1,611,864
Estimated value
Report date: 21 Apr 2025
Price
Ownership: Through Deerfield Private Design Fund V, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Oncorus, Inc.

Security class: Common Stock
Shares / value: 1,156,309
Estimated value
Report date: 30 Dec 2022
Price
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Oncorus, Inc.

Security class: Common Stock
Shares / value: 1,156,308
Estimated value
Report date: 30 Dec 2022
Price
Ownership: Through Deerfield Private Design Fund III, L.P.

Form 4 holding Director, Director by deputization

Acutus Medical, Inc.

Security class: Series A Common Stock Equivalent Convertible Preferred Stock
Shares / value: 948,395
Estimated value
Report date: 27 Jan 2025
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Class A Common Stock
Underlying amount: 948,395

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Voting Common Stock
Shares / value: 940,352
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Voting Common Stock
Shares / value: 940,352
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Private Design Fund III, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Public Warrants
Shares / value: 625,000
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Public Warrants
Shares / value: 625,000
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through Deerfield Private Design Fund IV, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Oncorus, Inc.

Security class: Common Stock
Shares / value: 284,697
Estimated value
Report date: 30 Dec 2022
Price
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Series A Common Stock Equivalent Convertible Preferred Stock
Shares / value: 58,945
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Series A Common Stock Equivalent Convertible Preferred Stock
Shares / value: 58,945
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through Deerfield Private Design Fund IV, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 55,150
Estimated value
Report date: 19 May 2026
Price
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, *Director by Deputization

BiomX Inc.

Security class: Series X Non-Voting Convertible Preferred Stock
Shares / value: 47,957
Estimated value
Report date: 15 Jul 2024
Price
Ownership: Through Deerfield Healthcare Innovations Fund II, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, *Director by Deputization

BiomX Inc.

Security class: Series X Non-Voting Convertible Preferred Stock
Shares / value: 47,957
Estimated value
Report date: 15 Jul 2024
Price
Ownership: Through Deerfield Private Design Fund V, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Series A Common Stock Equivalent Convertible Preferred Stock
Shares / value: 45,620
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through DFP Sponsor, LLC
Underlying class: Class A Common Stock
Underlying amount: 4,562,000

Form 4 holding Director, *Director by Deputization

BiomX Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 17,600
Estimated value
Report date: 14 Apr 2025
Price
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 4,147
Estimated value
Report date: 18 Jun 2025
Price
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Director, Director by deputization

Acutus Medical, Inc.

Security class: Warrant to Purchase Common Stock
Shares / value: 0
Estimated value
Report date: 27 Jan 2025
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Class A Common Stock
Underlying amount: 31,116

Form 4 holding Director, Director by deputization

Acutus Medical, Inc.

Security class: Warrant to Purchase Common Stock
Shares / value: 0
Estimated value
Report date: 27 Jan 2025
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Class A Common Stock
Underlying amount: 193,002

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Bicara Therapeutics Inc.

Security class: Series C Preferred Stock
Shares / value: 0
Estimated value
Report date: 17 Sep 2024
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Bicara Therapeutics Inc.

Security class: Series C Preferred Stock
Shares / value: 0
Estimated value
Report date: 17 Sep 2024
Price
Ownership: Through Deerfield Private Design Fund V, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, Director by Deputization, 10%+ Owner

CareMax, Inc.

Security class: Restricted Stock Units
Shares / value: 0
Estimated value
Report date: 17 Nov 2023
Price: $3.46
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Fractyl Health, Inc.

Security class: Series C-2 Preferred Stock
Shares / value: 0
Estimated value
Report date: 06 Feb 2024
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Fractyl Health, Inc.

Security class: Series D Preferred Stock
Shares / value: 0
Estimated value
Report date: 06 Feb 2024
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class A Common Stock - Restricted Stock Units
Shares / value: 0
Estimated value
Report date: 15 Jul 2026
Price
Ownership: Through Deerfield Mangement Company, L.P.

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class B Common Stock
Shares / value: 0
Estimated value
Report date: 15 Jul 2026
Price
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Class B Common Stock
Shares / value: 0
Estimated value
Report date: 15 Jul 2026
Price
Ownership: Through Deerfield Private Design Fund IV, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Director, Director by Deputization, 10%+ Owner

Nuvalent, Inc.

Security class: Stock Option (right to buy)
Shares / value: 0
Estimated value
Report date: 15 Jul 2026
Price
Ownership: Through Deerfield Mangement Company, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Class B Common Stock
Shares / value: 0
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Members of 10% Group, 10%+ Owner

Oncology Institute, Inc.

Security class: Class B Common Stock
Shares / value: 0
Estimated value
Report date: 12 Nov 2021
Price
Ownership: Through DFP Sponsor, LLC
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series A Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series A Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series B Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series B Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series C Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series C Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series D Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Parabilis Medicines, Inc.

Security class: Series D Preferred Stock
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Through Deerfield Private Design Fund III, L.P.
Underlying class: Voting Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

PepGen Inc.

Security class: Series B Preferred Stock
Shares / value: 0
Estimated value
Report date: 10 May 2022
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

PepGen Inc.

Security class: Series B Preferred Stock
Shares / value: 0
Estimated value
Report date: 10 May 2022
Price
Ownership: Through Deerfield Private Design Fund V, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

Singular Genomics Systems, Inc.

Security class: 6% Convertible Note due 2023
Shares / value: 0
Estimated value
Report date: 01 Jun 2021
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

Singular Genomics Systems, Inc.

Security class: 6% Convertible Note due 2023
Shares / value: 0
Estimated value
Report date: 01 Jun 2021
Price
Ownership: Through Deerfield Private Design Fund IV, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding *Possible Member of 10% Group, 10%+ Owner

Singular Genomics Systems, Inc.

Security class: Series B Preferred Stock
Shares / value: 0
Estimated value
Report date: 01 Jun 2021
Price
Ownership: Through Deerfield Private Design Fund IV, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Xilio Therapeutics, Inc.

Security class: Series C Preferred Stock
Shares / value: 0
Estimated value
Report date: 26 Oct 2021
Price
Ownership: Through Deerfield Partners, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Possible Member of 10% Group, 10%+ Owner

Xilio Therapeutics, Inc.

Security class: Series C Preferred Stock
Shares / value: 0
Estimated value
Report date: 26 Oct 2021
Price
Ownership: Through Deerfield Private Design Fund V, L.P.
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by James E. Flynn

4 NUVL

Nuvalent, Inc.

Report period: 15 Jul 2026
Transactions: 18
Transaction value: $0
Accepted by SEC: 17 Jul 2026, 15:27
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 16 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 18 Jun 2026, 18:35
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 PBLS

Parabilis Medicines, Inc.

Report period: 11 Jun 2026
Transactions: 16
Transaction value: $0
Accepted by SEC: 11 Jun 2026, 20:07
Role: Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

3 PBLS

Parabilis Medicines, Inc.

Report period: 09 Jun 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 09 Jun 2026, 21:15
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 19 May 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 May 2026, 20:02
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 27 Feb 2026
Transactions: 4
Transaction value: +$25,000,000
Accepted by SEC: 02 Mar 2026, 19:46
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 24 Nov 2025
Transactions: 2
Transaction value: -$70,874,975
Accepted by SEC: 24 Nov 2025, 20:00
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 31 Jul 2025
Transactions: 3
Transaction value: +$30,000,000
Accepted by SEC: 04 Aug 2025, 18:28
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 SPRY

ARS Pharmaceuticals, Inc.

Report period: 27 Jun 2025
Transactions: 2
Transaction value: -$13,663,151
Accepted by SEC: 01 Jul 2025, 16:42
Role: 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 18 Jun 2025
Transactions: 4
Transaction value: $0
Accepted by SEC: 20 Jun 2025, 21:08
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 13 May 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 May 2025, 19:44
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 PHGE

BiomX Inc.

Report period: 21 Apr 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 23 Apr 2025, 17:49
Role: Director, *Director by Deputization
Next action: Open filing details

4 PHGE

BiomX Inc.

Report period: 14 Apr 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 18 Apr 2025, 17:28
Role: Director, *Director by Deputization
Next action: Open filing details

4 PHGE

BiomX Inc.

Report period: 27 Feb 2025
Transactions: 6
Transaction value: +$657,467
Accepted by SEC: 03 Mar 2025, 19:02
Role: Director, *Director by Deputization
Next action: Open filing details

4 AFIB

Acutus Medical, Inc.

Report period: 27 Jan 2025
Transactions: 5
Transaction value: $0
Accepted by SEC: 28 Jan 2025, 21:00
Role: Director, Director by deputization
Next action: Open filing details

4 SPRY

ARS Pharmaceuticals, Inc.

Report period: 11 Nov 2024
Transactions: 8
Transaction value: -$10,143,706
Accepted by SEC: 13 Nov 2024, 20:16
Role: 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 22 Oct 2024
Transactions: 2
Transaction value: -$195,500,000
Accepted by SEC: 24 Oct 2024, 16:08
Role: Director, * Director by deputization, 10%+ Owner
Next action: Open filing details

4 BCAX

Bicara Therapeutics Inc.

Report period: 17 Sep 2024
Transactions: 6
Transaction value: +$1,260,000
Accepted by SEC: 17 Sep 2024, 18:16
Role: Possible Members of 10% Group, 10%+ Owner
Next action: Open filing details

3 BCAX

Bicara Therapeutics Inc.

Report period: 12 Sep 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 12 Sep 2024, 21:07
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 PHGE

BiomX Inc.

Report period: 15 Jul 2024
Transactions: 4
Transaction value: $0
Accepted by SEC: 17 Jul 2024, 18:09
Role: Director, *Director by Deputization
Next action: Open filing details

4 PHGE

BiomX Inc.

Report period: 11 Jul 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Jul 2024, 19:19
Role: Director, *Director by Deputization
Next action: Open filing details

4 PHGE

BiomX Inc.

Report period: 09 Jul 2024
Transactions: 4
Transaction value: $0
Accepted by SEC: 11 Jul 2024, 18:47
Role: Director, *Director by Deputization, 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 12 Jun 2024
Transactions: 4
Transaction value: $0
Accepted by SEC: 14 Jun 2024, 17:05
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 29 May 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Jun 2024, 18:31
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 PHGE

BiomX Inc.

Report period: 15 Mar 2024
Transactions: 6
Transaction value: $0
Accepted by SEC: 19 Mar 2024, 21:39
Role: Director, *Director by Deputization, 10%+ Owner
Next action: Open filing details

3 PHGE

BiomX Inc.

Report period: 15 Mar 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 19 Mar 2024, 21:28
Role: Director, *Director by Deputization
Next action: Open filing details

4 AHCO

AdaptHealth Corp.

Report period: 08 Mar 2024
Transactions: 5
Transaction value: -$3,815,704
Accepted by SEC: 12 Mar 2024, 19:01
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

3 AHCO

AdaptHealth Corp.

Report period: 27 Feb 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 08 Mar 2024, 17:43
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 16 Feb 2024
Transactions: 3
Transaction value: +$37,499,993
Accepted by SEC: 16 Feb 2024, 14:37
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 GUTS

Fractyl Health, Inc.

Report period: 06 Feb 2024
Transactions: 4
Transaction value: $0
Accepted by SEC: 08 Feb 2024, 14:07
Role: Possible Members of 10% Group, 10%+ Owner
Next action: Open filing details

3 GUTS

Fractyl Health, Inc.

Report period: 01 Feb 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 01 Feb 2024, 18:55
Role: Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

CareMax, Inc.

Report period: 17 Nov 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 21 Nov 2023, 18:09
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 15 Jun 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 16 Jun 2023, 18:46
Role: Director, Director by deputization, 10%+ Owner
Next action: Open filing details

CareMax, Inc.

Report period: 08 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 12 Jun 2023, 20:18
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 09 May 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 11 May 2023, 18:31
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

Oncorus, Inc.

Report period: 28 Dec 2022
Transactions: 9
Transaction value: -$88,254
Accepted by SEC: 30 Dec 2022, 18:16
Role: Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

Oncorus, Inc.

Report period: 22 Dec 2022
Transactions: 6
Transaction value: -$19,897
Accepted by SEC: 27 Dec 2022, 17:33
Role: Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

Oncorus, Inc.

Report period: 19 Dec 2022
Transactions: 9
Transaction value: -$37,628
Accepted by SEC: 21 Dec 2022, 18:09
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

Oncorus, Inc.

Report period: 13 Dec 2022
Transactions: 9
Transaction value: -$5,332
Accepted by SEC: 15 Dec 2022, 17:50
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

CareMax, Inc.

Report period: 17 Nov 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 21 Nov 2022, 18:31
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

Frazier Lifesciences Acquisition Corp

Report period: 08 Nov 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 14 Nov 2022, 17:12
Role: Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

3 SPRY

ARS Pharmaceuticals, Inc.

Report period: 08 Nov 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 10 Nov 2022, 18:48
Role: Director, Director by deputization, 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 03 Nov 2022
Transactions: 1
Transaction value: +$21,775,000
Accepted by SEC: 07 Nov 2022, 17:24
Role: Director, Director by deputization, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 16 Sep 2022
Transactions: 4
Transaction value: +$34,999,990
Accepted by SEC: 20 Sep 2022, 20:31
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 AFIB

Acutus Medical, Inc.

Report period: 30 Jun 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 05 Jul 2022, 17:27
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 AFIB

Acutus Medical, Inc.

Report period: 16 Jun 2022
Transactions: 4
Transaction value: $0
Accepted by SEC: 20 Jun 2023, 20:10
Role: Director, Director by deputization
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 16 Jun 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 21 Jun 2022, 16:14
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 MIRM

Mirum Pharmaceuticals, Inc.

Report period: 06 Jun 2022
Transactions: 6
Transaction value: -$962,256
Accepted by SEC: 08 Jun 2022, 19:25
Role: * Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 10 May 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 11 May 2022, 17:42
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 PEPG

PepGen Inc.

Report period: 10 May 2022
Transactions: 6
Transaction value: +$4,999,992
Accepted by SEC: 10 May 2022, 18:22
Role: Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

3 PEPG

PepGen Inc.

Report period: 05 May 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 05 May 2022, 20:00
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 TOI

Oncology Institute, Inc.

Report period: 12 Nov 2021
Transactions: 11
Transaction value: +$100,000,000
Accepted by SEC: 16 Nov 2021, 20:34
Role: Possible Members of 10% Group, 10%+ Owner
Next action: Open filing details

4 XLO

Xilio Therapeutics, Inc.

Report period: 26 Oct 2021
Transactions: 6
Transaction value: +$12,400,000
Accepted by SEC: 28 Oct 2021, 19:15
Role: Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

3 XLO

Xilio Therapeutics, Inc.

Report period: 21 Oct 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 21 Oct 2021, 21:36
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 02 Aug 2021
Transactions: 14
Transaction value: +$10,200,000
Accepted by SEC: 04 Aug 2021, 18:05
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 NUVL

Nuvalent, Inc.

Report period: 28 Jul 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 30 Jul 2021, 17:27
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

3 NUVL

Nuvalent, Inc.

Report period: 28 Jul 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 28 Jul 2021, 18:58
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 AFIB

Acutus Medical, Inc.

Report period: 19 Jul 2021
Transactions: 2
Transaction value: +$14,999,992
Accepted by SEC: 21 Jul 2021, 17:14
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

4 MIRM

Mirum Pharmaceuticals, Inc.

Report period: 09 Jul 2021
Transactions: 1
Transaction value: -$1,570,328
Accepted by SEC: 13 Jul 2021, 12:06
Role: * Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 MIRM

Mirum Pharmaceuticals, Inc.

Report period: 02 Jul 2021
Transactions: 3
Transaction value: -$1,086,222
Accepted by SEC: 07 Jul 2021, 18:48
Role: * Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 30 Jun 2021
Transactions: 3
Transaction value: +$5,999,962
Accepted by SEC: 02 Jul 2021, 17:07
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

4 AFIB

Acutus Medical, Inc.

Report period: 17 Jun 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 02 Sep 2021, 20:17
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

Deerfield Healthcare Technology Acquisitions Corp.

Report period: 08 Jun 2021
Transactions: 8
Transaction value: +$100,000,000
Accepted by SEC: 10 Jun 2021, 17:48
Role: Director, Director by Deputization, 10%+ Owner
Next action: Open filing details

Singular Genomics Systems, Inc.

Report period: 01 Jun 2021
Transactions: 8
Transaction value: +$33,315,610
Accepted by SEC: 03 Jun 2021, 17:04
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

Singular Genomics Systems, Inc.

Report period: 26 May 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 26 May 2021, 21:24
Role: *Possible Member of 10% Group, 10%+ Owner
Next action: Open filing details

4 LRMR

Larimar Therapeutics, Inc.

Report period: 12 May 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 May 2021, 17:17
Role: Director, * Director by Deputization, 10%+ Owner
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for James E. Flynn

Insider Reports Filed by James E. Flynn